You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 18, 2024

Details for Patent: 11,746,102


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,746,102 protect, and when does it expire?

Patent 11,746,102 protects XPOVIO and is included in one NDA.

This patent has thirty-two patent family members in eighteen countries.


Drugs Protected by US Patent 11,746,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-001 Jul 3, 2019 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED FOR THE TREATMENT OF ADULT PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), NOT OTHERWISE SPECIFIED, INCLUDING DLBCL ARISING FROM FOLLICULAR LYMPHOMA, AFTER AT LEAST 2 LINES OF SYSTEMIC THERAPY ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-002 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED IN COMBINATION WITH BORTEZOMIB AND DEXAMETHASONE FOR THE TREATMENT OF ADULT PATIENTS WITH MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PRIOR THERAPY ⤷  Sign Up
Karyopharm Theraps XPOVIO selinexor TABLET;ORAL 212306-003 Apr 15, 2021 RX Yes No ⤷  Sign Up ⤷  Sign Up XPOVIO IS INDICATED IN COMBINATION WITH DEXAMETHASONE TO TREAT RELAPSED OR REFRACTORY MULTIPLE MYELOMA (REFRACTORY TO AT LEAST AN ANTI-CD38 MAB, 2 PROTEASOME INHIBITORS AND 2 IMMUNOMODULATORY AGENTS) IN ADULTS WHO RECEIVED AT LEAST 4 PRIOR THERAPIES ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,746,102

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2015301484 ⤷  Sign Up
Australia 2020203246 ⤷  Sign Up
Australia 2021286266 ⤷  Sign Up
Australia 2024202835 ⤷  Sign Up
Canada 2957266 ⤷  Sign Up
China 107072992 ⤷  Sign Up
China 111481553 ⤷  Sign Up
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.